in high cardiovascular risk patients with suboptimally
controlled hypercholesterolemia at baseline despite receiving maximally tolerated statin with or without other lipid-lowering
therapy. The frequency of treatment-emergent adverse events and study medication discontinuations were generally
comparable between treatment groups.